Cross-sectional telomere study and machine-learning analysis in adults with type 2 diabetes after COVID-19
Source check: Source checked. Not independent scientific confirmation.
Finding: In a cross-sectional pilot of adults with type 2 diabetes, leukocyte telomere length was shorter among those with post-COVID syndrome than those without it. Machine-learning models were also evaluated for identifying syndrome status; this observational association does not establish telomere shortening as a cause.
Technology: Machine-learning classification of post-COVID syndrome using clinical and telomere-related variables.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Machine-learning classification of post-COVID syndrome using clinical and telomere-related variables.
- Test and result
- Cross-sectional groups comprised 44 participants with post-COVID syndrome and 22 without; mean telomere length was 1.09±0.19 versus 1.28±0.24 (p=.001); reported gradient-boosting AUC was .753.
- Limitation / still unknown
- Single-center pilot, cross-sectional association and model evaluation; no causal inference or prospective clinical benefit established.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12425890/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.